Managing Uncomplicated Acute Bacterial Rhinosinusitis with Non-Type 1 Penicillin Hypersensitivity
Patients with uncomplicated acute bacterial rhinosinusitis (ABRS) who carry a non-type 1 penicillin hypersensitivity require a specific management pathway. This protocol addresses that scenario directly.
Clinical Scenario
Non-Type 1 Penicillin Hypersensitivity
ABRS is diagnosed when symptoms — purulent nasal drainage with nasal obstruction, facial pain-pressure-fullness, or both — persist without improvement for at least 10 days from onset of upper respiratory symptoms, or worsen within 10 days after an initial improvement (double worsening). The patient's non-type 1 penicillin hypersensitivity is the key factor shaping management decisions in this scenario.
Initial Approach
For adults with uncomplicated ABRS — including those with non-type 1 penicillin hypersensitivity — current guidance supports an initial period of watchful waiting without antibiotics, complemented by symptomatic support. The full structured protocol defines the complete pathway: timing, conditions for reassessment, and the specific management options for this population.
References
DOI: 10.1002/ohn.1344
- A clinician should diagnose ABRS when (a) symptoms or signs of acute rhinosinusitis (purulent nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without evidence of improvement for at least 10 days beyond the onset of upper respiratory symptoms, or (b) symptoms or signs of acute rhinosinusitis worsen within 10 days after an initial improvement (double worsening).
- Clinicians should offer watchful waiting (without antibiotics) for adults with uncomplicated ABRS with assurance of follow-up.
- Specific to this CPG update, watchful waiting for ABRS is clarified as lasting 3 to 5 days after diagnosis of ABRS in contrast to a potential 7 days after diagnosis in prior guidelines.
- Clinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of ABRS.
View source ↗